Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 2Adenomatous Polyposis Coli 2Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Duodenal Neoplasms 1Attenuated familial adenomatous polyposis 1

Interventions

venetoclax 30Rituximab 26ibrutinib 22acalabrutinib 22Cyclophosphamide 22Specimen Handling 20obinutuzumab 17Biopsy 15fludarabine 13zanubrutinib 11pirtobrutinib 10fludarabine phosphate 10Magnetic Resonance Spectroscopy 9Bendamustine Hydrochloride 9Lenalidomide 7CT-P10 7idelalisib 6Whole-Body Irradiation 6Mycophenolic Acid 6ARQ531 6Cyclosporine 5Vincristine 4Sirolimus 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Doxorubicin 4Blood Component Removal 4pembrolizumab 3Tacrolimus 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Endoscopy, Gastrointestinal × 90 days × Clear all
NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡